Results
19
Defensive mid-caps and large-caps in descending order of expected ROE in three years.
19 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
---|---|---|---|---|---|---|---|---|---|---|
IMB | UK£27.42 | 2.7% | 44.9% | UK£22.6b | UK£28.34 | PE8.6x | S-13.3% | 5.6% | ||
ULVR | UK£46.03 | -0.9% | 16.3% | UK£120.2b | UK£50.27 | PE21.6x | E7.4% | 3.1% | ||
GSK | UK£13.80 | -0.5% | -16.5% | UK£57.1b | UK£17.94 | PE22.4x | E20.8% | 4.2% | ||
RKT | UK£52.36 | 0.3% | -9.6% | UK£36.3b | UK£57.43 | PE23.2x | E10.7% | 3.7% | ||
AZN | UK£110.30 | -1.3% | 4.7% | UK£174.8b | UK£138.45 | PE32.9x | E16.9% | 2.1% | ||
DGE New | UK£23.28 | -6.7% | -21.7% | UK£52.6b | UK£26.42 | PE18x | E7.3% | 3.6% | ||
CCH | UK£28.94 | 2.7% | 26.4% | UK£10.4b | UK£30.50 | PE19.9x | E12.6% | 2.7% | ||
HIK | UK£22.72 | 2.7% | 18.3% | UK£5.1b | UK£23.90 | PE22.1x | E11.0% | 2.8% | ||
CTEC | UK£2.39 | -4.6% | 0.3% | UK£5.0b | UK£2.99 | PE39.8x | E18.6% | 2.0% | ||
TSCO | UK£3.77 | 1.8% | 30.2% | UK£24.9b | UK£4.04 | PE13.3x | E1.4% | 3.3% | ||
CNA | UK£1.41 | 3.3% | 5.8% | UK£7.1b | UK£1.67 | PE6.4x | E-8.0% | 3.0% | ||
BATS | UK£32.20 | 1.5% | 36.3% | UK£70.4b | UK£33.35 | PS2.7x | E42.2% | 7.3% | ||
SSE | UK£16.15 | 2.0% | -3.3% | UK£17.8b | UK£21.62 | PE9.3x | E7.0% | 3.8% | ||
TATE | UK£6.46 | -2.3% | 3.4% | UK£2.9b | UK£8.59 | PE18.3x | E14.3% | 3.0% | ||
SN. | UK£10.34 | 0.8% | -7.5% | UK£9.0b | UK£12.48 | PE36.9x | E19.8% | 2.9% | ||
DRX | UK£6.23 | 2.2% | 33.3% | UK£2.3b | UK£8.43 | PE3.5x | E-31.8% | 3.9% | ||
ABF | UK£18.43 | -4.0% | -18.9% | UK£13.4b | UK£22.78 | PE9.2x | E4.2% | 4.9% | ||
NG. | UK£9.84 | 1.4% | -5.0% | UK£48.2b | UK£11.25 | PE27.9x | E16.0% | 5.6% | ||
SBRY | UK£2.57 | 0% | -6.7% | UK£5.8b | UK£3.02 | PE33.9x | E20.3% | 5.1% |